New drug shows promise against tough breast cancers
NCT ID NCT04699630
First seen Jan 11, 2026 · Last updated May 23, 2026 · Updated 18 times
Summary
This study tested an experimental drug called U3-1402 (patritumab deruxtecan) in 121 people with advanced or metastatic breast cancer. The goal was to see if the drug could shrink tumors and to check for side effects. The drug is designed to target cancer cells directly, and the results help doctors understand if it might be a useful treatment option.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC BREAST CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
City of Hope
Duarte, California, 91010, United States
-
Florida Cancer Specialists-North
St. Petersburg, Florida, 33705, United States
-
Florida Cancer Specialists-South
Fort Myers, Florida, 33901, United States
-
Fred Hutchinson Cancer Center
Seattle, Washington, 98109, United States
-
Highlands Oncology Group
Springdale, Arkansas, 72762, United States
-
Levine Cancer Institute
Charlotte, North Carolina, 28204, United States
-
Rutgers-Cancer Institute of New Jersey
New Brunswick, New Jersey, 08903, United States
-
SCRI Oncology Partners
Nashville, Tennessee, 37203, United States
-
Tennessee Oncology
Nashville, Tennessee, 37203, United States
-
University of Alabama at Birmingham
Birmingham, Alabama, 35249, United States
-
Washington University School of Medicine
St Louis, Missouri, 63110, United States
Conditions
Explore the condition pages connected to this study.